Immunoconjugates in the management of hairy cell leukemia.

Abstract excerpt

Hairy cell leukemia (HCL) is an indolent B-cell malignancy effectively treated but not often cured by purine analog therapy; after multiple courses of purine analogs, patients can become purine analog resistant and in need of alternative therapies. Complete remission to single-agent purine analog is often accompanied by minimal residual disease (MRD), residual HCL cells detectable by immunologic methods,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacterial Toxins
• Share to Clinical Trials as Topic
• Share to Exotoxins